利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.032 秒)

    Quinone derivatives, their production and use
    2.
    发明授权
    Quinone derivatives, their production and use 失效
    喹诺酮衍生物，其生产和使用

    公开(公告)号：US5229385A

    公开(公告)日：1993-07-20

    申请号：US818856

    申请日：1992-01-10

    申请人： Shinji Terao ,  Kohei Nishikawa

    发明人： Shinji Terao ,  Kohei Nishikawa

    IPC分类号： C07D213/50 ,  C07D213/55 ,  C07D409/06 ,  C07D521/00

    CPC分类号： C07D231/12 ,  C07D213/50 ,  C07D213/55 ,  C07D233/56 ,  C07D249/08 ,  C07D409/06

    摘要： Quinone derivatives represented by the general formula ##STR1## (wherein, R.sup.1 and R.sup.2, the same or different, refer to hydrogen atom, methyl or methoxymethyl group, or R.sup.1 and R.sup.2 bind together to form --CH.dbd.CH--CH.dbd.CH--; R.sup.3 is hydrogen atom or methyl group; R.sup.4 is nitrogen-containing heterocyclic group which may be substituted; R.sup.5 is hydrogen atom, methyl group, hydroxymethyl group which may be substituted, or carboxyl group which may be esterified or amidated; Z is ##STR2## (wherein, R' is hydrogen atom or methyl group); n is an integer from 0 through 12, m is an integer from 0 through 3, and k is an integer from 0 through 7, providing that, when m is 2 or 3, Z and k are able to vary appropriately in the repeating unit shown in []), and the hydroquinone derivatives thereof, are novel compounds, possess improvement effects of metabolism of poly unsaturated fatty acids, particularly two or more of inhibition of production of fatty acid peroxides, inhibition of production of metabolites in 5-lipoxygenase pathway, inhibition of thromboxane A.sub.2 synthetase, thromboxane A.sub.2 receptor antagonism and scavenging action of active oxygen species, and of use as drugs, such as antithrombotics, anti-vascular constriction agents, anti-asthma agent, antiallergic agents, therpeutics for psoriasis, agents for improvement in heart, brain and cardiovascular systems, therapeutics for nephritis, active oxygen-eliminating agents, anticancer agents, agents for improvement of control of arachidonate cascade products, etc.

    摘要翻译： 由通式（I）表示的醌酮衍生物（其中，R1和R2相同或不同，指氢原子，甲基或甲氧基甲基，或R1和R2结合在一起形成-CH = CH-CH = CH-; R3是氢原子或甲基; R4是可以被取代的含氮杂环基; R5是氢原子，甲基，可被取代的羟甲基，或可被酯化或酰胺化的羧基; Z是 （其中，R'为氢原子或甲基）; n为0〜12的整数，m为0〜3的整数，k为0〜7的整数， 当m为2或3时，Z和k能够在[]）所示的重复单元中适当变化，并且其氢醌衍生物是新型化合物，具有改善多不饱和脂肪酸代谢的效果，特别是两种或更多种 抑制脂肪酸过氧化物的产生，抑制代谢物的产生 在5-脂氧合酶途径中，血栓烷A2合成酶的抑制，血栓素A2受体拮抗作用和活性氧的清除作用，以及用作药物，如抗血栓形成剂，抗血管收缩剂，抗哮喘药，抗过敏剂，治疗剂 牛皮癣，改善心脏，脑和心血管系统的药剂，肾炎治疗剂，活性氧消除剂，抗癌剂，改善花生四烯酸级联产物的控制剂等。

    Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
    3.
    发明授权
    Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines 失效
    抑制3-（1-烯基）吡啶的血栓烷合成酶

    公开(公告)号：US4563446A

    公开(公告)日：1986-01-07

    申请号：US632332

    申请日：1984-07-19

    申请人： Shinji Terao ,  Kohei Nishikawa

    发明人： Shinji Terao ,  Kohei Nishikawa

    IPC分类号： C07D213/02 ,  C07D213/06 ,  C07D213/16 ,  C07D213/26 ,  C07D213/30 ,  C07D213/48 ,  C07D213/55 ,  C07D213/56 ,  C07D213/57 ,  C07D213/80 ,  C07D213/89 ,  C07D401/06 ,  C07D405/02 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D521/00 ,  C07F7/18 ,  C07D213/59 ,  C07D213/24 ,  A61K31/44

    CPC分类号： C07D213/16 ,  C07D213/26 ,  C07D213/30 ,  C07D213/48 ,  C07D213/55 ,  C07D213/56 ,  C07D213/57 ,  C07D213/80 ,  C07D213/89 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D405/06 ,  C07D409/06 ,  C07F7/1856

    摘要： Novel compounds of the formula: ##STR1## wherein R.sup.2 is an aromatic or heterocyclic group, which may optionally be substituted, R.sup.2 is a methyl group, a hydroxymethyl group, a nitroxymethyl group, a formyl group, a nitrogen-containing five-membered ring-methyl group, an acetal-methyl group, a trialkylsilyloxymethyl group, an alkyl- or aryl-sulfonyloxymethyl group, an alkyl- or aryl-sulfonylaminocarbonyloxymethyl group, an acyloxymethyl group, an alkoxycarbonyloxymethyl group, a halogenomethyl group, an alkoxymethyl group, an aryloxymethyl group, a cyano group, a carbamoyl group which may optionally be substituted, a carbamoyloxymethyl group which may optionally be substituted, a thiocarbamoyloxymethyl group which may optionally be substituted, and an alkoxycarbonyl group, n is an integer of 1 to 20, and ##STR2## provided that n is an integer of 9 to 20 when ##STR3## and, at the same time, R.sup.2 is a carboxyl group or an alkoxycarbonyl group, or a pharmacologically acceptable salt thereof, have a selective inhibitory action on biosynthesis of thromboxane A.sub.2 (TXA.sub.2) and an effect of enhancing the production of prostaglandin I.sub.2 (PGI.sub.2), and can be used for mammals to prevent and treat arterial thrombosis caused by platelet aggregation or ischemic diseases caused by vasospasms in cardiac, cerebral and peripheral circulatory system (e.g. cardiac infarction, stroke, occlusion of blood vessels in kidney, lung and other organs, pectic ulcer, etc.).

    摘要翻译： 下式的新型化合物：其中R 2为可任意取代的芳族或杂环基，R 2为甲基，羟甲基，硝酰甲基，甲酰基，含氮五元环 甲基，缩醛 - 甲基，三烷基甲硅烷氧基甲基，烷基 - 或芳基 - 磺酰氧基甲基，烷基 - 或芳基 - 磺酰基氨基羰基氧基甲基，酰氧基甲基，烷氧基羰氧基甲基，卤代甲基，烷氧基甲基， 基团，氰基，可以任意取代的氨基甲酰基，可任意取代的氨基甲酰氧基甲基，可任意取代的硫代氨基甲酰氧基甲基，烷氧基羰基，n为1〜20的整数，＆lt; IMAGE >条件是当中n为9〜20的整数，并且同时R2为羧基或烷氧基羰基时，或其药理学上可接受的盐具有 对血栓素A2（TXA2）的生物合成的选择性抑制作用和增强前列腺素I2（PGI2）的产生的作用，可用于哺乳动物预防和治疗血小板聚集或心脏血管痉挛引起的缺血性疾病引起的动脉血栓形成 ，脑和周围循环系统（例如， 心脏梗死，中风，肾脏，肺部和其他器官中血管闭塞，果胶性溃疡等）。

    Manufacturing method of semiconductor device and semiconductor manufacturing device
    4.
    发明申请
    Manufacturing method of semiconductor device and semiconductor manufacturing device 失效
    半导体器件和半导体制造器件的制造方法

    公开(公告)号：US20060057860A1

    公开(公告)日：2006-03-16

    申请号：US11207064

    申请日：2005-08-18

    申请人： Shinji Terao

    发明人： Shinji Terao

    IPC分类号： H01L21/31

    CPC分类号： H01L21/02238 ,  H01L21/02255 ,  H01L21/31662 ,  H01L21/67253

    摘要： A manufacturing method of a semiconductor device, comprises; a process of heat-treating a semiconductor substrate under the ordinary pressure and in an oxidizing atmosphere; and a process of heat-treating the semiconductor substrate under the ordinary pressure and in an inert atmosphere, wherein heat-treating time or heat-treating temperature in heat treatment in the oxidizing atmosphere is changed based on the fluctuation of atmospheric pressure, and the heat-treating time in the inert atmosphere is determined based on the heat-treating time or the heat-treating temperature in the oxidizing atmosphere.

    摘要翻译： 一种半导体器件的制造方法，包括： 在常压和氧化气氛中对半导体衬底进行热处理的工艺; 以及在常压下和惰性气氛下对半导体基板进行热处理的工序，其中氧化气氛中的热处理时间或热处理温度根据大气压的波动而变化，热量 基于氧化气氛中的热处理时间或热处理温度来确定惰性气氛中的时间。

    Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system
    6.
    发明授权
    Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system 失效
    含有某些可用于预防和治疗循环系统疾病的抗坏血酸衍生物的药物组合物

    公开(公告)号：US4959362A

    公开(公告)日：1990-09-25

    申请号：US245943

    申请日：1988-09-19

    申请人： Shinji Terao ,  Minoru Hirata

    发明人： Shinji Terao ,  Minoru Hirata

    IPC分类号： A23L3/3463 ,  C07D307/62 ,  C07D405/12 ,  C07D405/14 ,  C07D407/04

    CPC分类号： C07D405/12 ,  A23L3/3463 ,  C07D307/62 ,  C07D405/14 ,  C07D407/04

    摘要： An ascorbic acid derivative of the formula: ##STR1## wherein R.sup.1 is organic residue having molecular weight of from 15 to 700, R.sup.2 is hydrogen or hydroxyl, R.sup.3 is hydrogen, acyl, optionally substituted phosphono or sulfo, and R.sup.3 and hydroxyl or R.sup.2 may form acetal residue or ketal residue, and a salt thereof are provided.The compound [I] and salts thereof have antioxidant activity and excellent prophylactic and improving actions on disorders of circulatory functions, and they are usefule as antioxidant agent for food and as agents of prophylaxis and improvement of circulatory functional disorders.

    摘要翻译： 一种下式的抗坏血酸衍生物：其中R1是分子量为15-700的有机残基，R2是氢或羟基，R3是氢，酰基，任选取代的膦酰基或磺基，R3和羟基 或R2可以形成缩醛残基或缩酮残基，并提供其盐。 化合物[I]及其盐具有抗氧化活性和对循环功能紊乱的优异的预防和改善作用，并且它们作为食品的抗氧化剂和用作预防和改善循环功能障碍的药物。

    Vinyl carboxylic acid derivatives, their production and use as inhibitors of thromboxane synthetase
    7.
    发明授权
    Vinyl carboxylic acid derivatives, their production and use as inhibitors of thromboxane synthetase 失效
    乙烯基羧酸衍生物，它们的生产和用作血栓素合成酶的抑制剂

    公开(公告)号：US4518602A

    公开(公告)日：1985-05-21

    申请号：US537862

    申请日：1983-09-30

    申请人： Shinji Terao ,  Kohei Nishikawa

    发明人： Shinji Terao ,  Kohei Nishikawa

    IPC分类号： C07C51/363 ,  C07D201/08 ,  C07D213/26 ,  C07D213/30 ,  C07D213/32 ,  C07D213/50 ,  C07D213/55 ,  C07D213/57 ,  C07D405/06 ,  C07D409/04 ,  C07D409/06 ,  C07F9/54 ,  A61K31/44 ,  C07D211/82 ,  C07D407/06

    CPC分类号： C07D213/30 ,  C07C51/363 ,  C07D201/08 ,  C07D213/26 ,  C07D213/32 ,  C07D213/50 ,  C07D213/55 ,  C07D213/57 ,  C07D405/06 ,  C07D409/04 ,  C07D409/06 ,  C07F9/5407

    摘要： Novel compound of the formula: ##STR1##wherein R.sup.1 is a pyridyl group; R.sup.2 is a phenyl, thienyl, furyl, naphthyl, benzothienyl or pyridyl group which may have as a substituent a lower alkoxy, a lower alkyl, a halogen, trifluoromethyl, a lower alkenyl or methylenedioxy; R.sup.3 is hydrogen, benzyl or a lower alkyl; one of R.sup.4 and R.sup.5 is hydrogen or a lower alkyl, and the other is an aryloxy, or lower aliphatic hydrocarbon, an alicyclic hydrocarbon having not more than 6 carbon atoms or an aromatic group which may have a substituent, or a group represented by the formula, --S(O).sub.m --R.sup.6 (in which R.sup.6 is phenyl or a lower alkyl group; m is an integer of 0 to 2), or R.sup.4 and R.sup.5 each combine with the other to represent one alkylene group; n is an integer of 2 to 6, or a pharmaceutically acceptable salt thereof has a selective inhibitory action on bio-synthesis of thromboxane A.sub.2 (TXA.sub.2) and an effect of enhancing the production of prostaglandin I.sub.2 (PGI.sub.2), and can be used in mammals for to prevention and treatment of arterial thrombosis caused by platelet aggregation or ischemic diseases caused by vasospasms in cardiac, cerebral and peripheral circulatory system (e.g. cardian infarction, apoplexy, infarct of blood vessels in kidney, lung and other organs, pectic ulcer, etc.).

    摘要翻译： 下式的新型化合物：其中R 1是吡啶基; R2是可以具有低级烷氧基，低级烷基，卤素，三氟甲基，低级烯基或亚甲二氧基的取代基的苯基，噻吩基，呋喃基，萘基，苯并噻吩基或吡啶基。 R3是氢，苄基或低级烷基; R4和R5中的一个是氢或低级烷基，另一个是芳氧基或低级脂族烃，不大于6个碳原子的脂环族烃或可以具有取代基的芳族基团，或由 式（-S（O）m -R 6（其中R 6为苯基或低级烷基; m为0〜2的整数），或者R 4和R 5各自与一个亚烷基结合， n为2〜6的整数，或其药学上可接受的盐对凝血恶烷A2（TXA2）的生物合成具有选择性抑制作用和增强前列腺素I2（PGI2）的产生的作用，可用于哺乳动物 用于预防和治疗由心脏，脑和周围循环系统（例如心脏梗塞，中风，肾脏，肺部和其他器官中的血管梗死，果胶性溃疡等）引起的血小板聚集或血管痉挛引起的缺血性疾病引起的动脉血栓形成。 ）。

    4-Hydroxy-3-pyrrolin-2-ones and treatment of circulatory disorders therewith
    10.
    发明授权
    4-Hydroxy-3-pyrrolin-2-ones and treatment of circulatory disorders therewith 失效
    4-羟基-3-吡咯啉-2-酮及其循环系统疾病的治疗

    公开(公告)号：US4925868A

    公开(公告)日：1990-05-15

    申请号：US84177

    申请日：1987-08-12

    申请人： Shinji Terao ,  Minoru Hirata

    发明人： Shinji Terao ,  Minoru Hirata

    IPC分类号： C07C59/64 ,  C07C59/68 ,  C07D207/38 ,  C07D277/06 ,  C07D333/20 ,  C07D333/32 ,  C07D409/06 ,  C07D487/04 ,  C07D513/04

    CPC分类号： C07D409/06 ,  C07C59/64 ,  C07C59/68 ,  C07D207/38 ,  C07D277/06 ,  C07D333/20 ,  C07D333/32 ,  C07D487/04 ,  C07D513/04

    摘要： The present invention relates to a compound of the formula: ##STR1## wherein X is sulfur or optionally substituted imino group; Y is a bond, oxygen, phenylene, phenyleneoxy, or oxyphenyleneoxy; R.sup.1 is hydrogen or optionally substituted hydrocarbon residue; R.sup.2 is optionally substituted hydrocarbon residue; and R.sup.1 may form, together with the imino-nitrogen atom as X, a nitrogen-containing 5- to 7-membered ring, production and use thereof.The compound (I) of the present invention has an anti-oxidation activity and activities of preventing or improving functional disorders due to biologically active oxygen species, thus being useful as a pharmaceutical agent for prophylaxis and therapy of disorders in the circulatory system.

    摘要翻译： 本发明涉及下式的化合物：其中X是硫或任选取代的亚氨基; Y是键，氧，亚苯基，亚苯氧基或氧亚苯氧基; R1是氢或任选取代的烃残基; R2是任选取代的烃残基; 并且R 1可以与亚氨基氮原子一起形成含氮的5-至7-元环，其生产和使用。 本发明的化合物（I）具有防止或改善由于生物活性氧物质引起的功能障碍的抗氧化活性和活性，因此可用作预防和治疗循环系统疾病的药剂。